The popularity of Ozempic has sparked a surge in the weight loss drug market, with China gearing up to launch its own competing medications, according to a report from the South China Morning Post.
Current analysts suggest that Eli Lilly’s Zepbound is leading the charge in the weight loss drug sector. Ozempic is certainly the most recognized name, yet it’s primarily designed for diabetics. The variant intended for general weight loss is called Wegovy, and there’s a growing concern about losing market share to Zepbound.
Wegovy has not performed as well as anticipated in sales, which, combined with a string of unsuccessful trials for next-generation products, has impacted Novo Nordisk’s stock prices. The Danish pharma company finds itself in a competitive market that is projected to exceed $150 billion in global worth in the next five years.
Many other pharmaceutical firms, including those implicated in scandals involving Chinese celebrities, are now aiming for a piece of this emerging market. The Hong Kong Association for the Study of Obesity noted that there are numerous potential candidates in development, and it is optimistic that three to five new drugs in this category will receive approval within the next five years.
Chow mentioned that there is increasing demand for obesity treatments in Hong Kong; however, availability is limited due to strict regulations on Western prescriptions. Eli Lilly’s slightly more affordable offerings still present a heavy financial burden for Asian consumers, prompting local firms like Butterfly to see an opening for more budget-friendly alternatives.
The first contender to hit the market could be Matid, a product from Hong Kong’s Innovative Biology. The company aims to secure approvals for both diabetes and weight control medications by the end of this year, with Innovent collaborating with Eli Lilly to help navigate the process.
“We believe we can concentrate on the Asian obesity market, especially in China and Japan, where there is still relatively low penetration and innovation is evolving.”
Analysts expect that Asia will see the fastest growth in demand for obesity medications over the coming years, as penetration by leading Western drugs has been limited.
Prices have been driven down for newer generation drugs, with some being nearly double as effective as their predecessors. Early obesity drugs from around the year 2000 aided weight loss of about 5%, while the newer generations, starting with Wegovy, can achieve over 20% weight loss.
There’s a belief among some analysts that Chinese companies might expedite the approval of next-generation obesity medications quicker than their Western counterparts. Meanwhile, the FDA has started to closely scrutinize weight loss drugs as their popularity skyrockets, leading to more products entering the market.
Although China’s obesity rate is lower than that of the US, the country’s massive population means it has a comparable number of individuals classified as clinically obese. Many Chinese women aspire to slimness, inspired by beauty influencers who suggest Ozempic if it’s accessible to them.
With high demand in China, plans are in motion to help Novo Nordisk secure a swift approval for Wegovy from local regulators. Eli Lilly is also seeking approval for its Tilzepatide products.
Nevertheless, companies like Innovative Biology and Hangzhou Jiu Jitsu Genetic Engineering might outpace them. Another Chinese firm, Huadong Medicine, has spent years attempting to secure patents against Ozempic’s protections, which were recently overturned in China.
A significant factor in the readiness of China’s weight loss drug market is the ease with which consumers can purchase medications online. Many have managed to acquire products like Ozempic without prescriptions, contributing to a substantial “gray market” filled with both legitimate and counterfeit items. Chinese authorities have tackled these gray markets over the past year, shutting down some of the more dangerous counterfeit drugs while clearing the path for verified medications.
The weight loss drug market is substantial enough that it holds diplomatic weight. The Chinese government has the capability to shift regulations to give domestic companies an edge, yet it is wary of discouraging foreign investors.
Prime Minister Li Chang has dedicated his time in office to promoting a narrative where China is “open for business.” However, Huadong Medicine’s efforts to undermine Ozempic’s patent highlights how the Chinese Communist Party might be tempted to push out Western weight loss pioneers from this lucrative market.
